Early biomarker opportunity Neurosteer focuses on objective biomarkers for early detection of Parkinson’s, Alzheimer’s, dementia and epilepsy, presenting a clear upsell to clinics and researchers conducting early-stage screening and prevention programs.

Wearable to cloud integration The adhesive forehead strip with pocket-sized transmitter feeds real-time EEG data to a cloud-based analytics platform, enabling scalable remote monitoring contracts with hospitals, clinics, and telemedicine providers.

Clinical trial enablement Real-time, decomposed EEG components and dashboards can streamline patient stratification and treatment optimization in neurodegenerative trials, offering sponsors measurable endpoints and faster study decisions.

Awarded credibility Consistent recognition as a Brain Health Company of the Year and keynote speaking engagements at AI and neurotech conferences build market credibility and open doors with potential enterprise customers and partners.

Scale-ready architecture Existing tech stack on AWS and cloud-based processing supports enterprise deployments, suggesting cross-sell potential to larger healthcare networks seeking integrated data pipelines, dashboards, and secure communications.